Analysts Issue Forecasts for Ocugen FY2025 Earnings

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Chardan Capital issued their FY2025 EPS estimates for shares of Ocugen in a research note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin forecasts that the company will earn ($0.25) per share for the year. Chardan Capital has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Ocugen's current full-year earnings is ($0.20) per share. Chardan Capital also issued estimates for Ocugen's FY2026 earnings at ($0.27) EPS.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of Ocugen in a research report on Thursday, March 6th.

Ocugen Stock Down 9.4 %

Shares of OCGN traded down $0.08 during midday trading on Thursday, reaching $0.72. 2,264,162 shares of the stock were exchanged, compared to its average volume of 5,088,229. The company has a market cap of $211.42 million, a price-to-earnings ratio of -4.02 and a beta of 3.88. The firm has a 50 day simple moving average of $0.67 and a 200-day simple moving average of $0.83. Ocugen has a 12-month low of $0.52 and a 12-month high of $2.08. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.04.

Ocugen (NASDAQ:OCGN - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). Ocugen had a negative return on equity of 154.75% and a negative net margin of 532.51%. The business had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. During the same period last year, the company earned ($0.03) earnings per share.

Remove Ads

Institutional Trading of Ocugen

A number of institutional investors and hedge funds have recently made changes to their positions in OCGN. Barclays PLC lifted its holdings in Ocugen by 104.3% in the 3rd quarter. Barclays PLC now owns 581,087 shares of the company's stock worth $577,000 after purchasing an additional 296,654 shares during the last quarter. Rhumbline Advisers raised its position in shares of Ocugen by 12.9% in the fourth quarter. Rhumbline Advisers now owns 324,475 shares of the company's stock valued at $261,000 after purchasing an additional 37,034 shares during the period. State Street Corp lifted its stake in shares of Ocugen by 7.1% in the third quarter. State Street Corp now owns 15,824,517 shares of the company's stock worth $15,701,000 after buying an additional 1,047,896 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Ocugen by 72.7% during the 4th quarter. SG Americas Securities LLC now owns 152,176 shares of the company's stock worth $123,000 after buying an additional 64,080 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in Ocugen in the 4th quarter valued at $40,000. Institutional investors and hedge funds own 10.27% of the company's stock.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.